You evidently misread the press release. The study in question (‘CONFIRM’) does not have a direct statistical comparison of BG-12 to Copaxone; rather, in this study, BG-12 and Copaxone were compared to placebo and each was found to be statsig better.
Although the BG-12 arms were numerically better than the Copaxone arm on the primary endpoint of annualized relapse rate, is it wrong to say (as you did) that BG-12 “beats Copaxone with ease” insofar as there was no statistical test for such a comparison.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.